Real-world Utilization of Mineralocorticoid Receptor Antagonists in India and the Benefits of GDMT in Heart Failure.

Early initiation of guideline-directed medical therapies (GDMTs) in heart failure (HF) and their uptitration to the target dose confer mortality benefits and reduce the risk of readmission. GDMT nonuse is a significant predictor of mortality in HF patients. However, GDMT prescription and adherence in India are low. Of the GDMTs, mineralocorticoid receptor antagonists (MRAs) are the least prescribed. There are multilevel gaps [healthcare professional (HCP)-related, patient-related] in the adoption and use of MRAs in HF. There is an unmet need to identify these gaps and formulate mitigation strategies to close them. This can improve or enhance GDMT adoption in the HF treatment paradigm.